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Abstract
Background
Type 2 diabetes (T2D) is a progressive disease whereby there is often deterioration in glu-
cose control despite escalation in treatment. There is significant heterogeneity to this pro-
gression of glycemia after onset of diabetes, yet the factors that influence glycemic
progression are not well understood. Given the tremendous burden of diabetes in the
Chinese population, and limited knowledge on factors that influence glycemia, we aim to
identify the clinical and genetic predictors for glycemic progression in Chinese patients with
T2D.
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Methods and findings
In 1995–2007, 7,091 insulin-naïve Chinese patients (mean age 56.8 ± 13.3 [SD] years;
mean age of T2D onset 51.1 ± 12.7 years; 47% men; 28.4% current or ex-smokers; median
duration of diabetes 4 [IQR: 1–9] years; mean HbA1c 7.4% ± 1.7%; mean body mass index
[BMI] 25.3 ± 4.0 kg/m2) were followed prospectively in the Hong Kong Diabetes Register.
We examined associations of BMI and other clinical and genetic factors with glycemic pro-
gression defined as requirement of continuous insulin treatment, or 2 consecutive HbA1c
�8.5% while on�2 oral glucose-lowering drugs (OGLDs), with validation in another multi-
center cohort of Hong Kong Diabetes Biobank. During a median follow-up period of 8.8
(IQR: 4.8–13.3) years, incidence of glycemic progression was 48.0 (95% confidence interval
[CI] 46.3–49.8) per 1,000 person-years with 2,519 patients started on insulin. Among the lat-
ter, 33.2% had a lag period of 1.3 years before insulin was initiated. Risk of progression was
associated with extremes of BMI and high HbA1c. On multivariate Cox analysis, early age
at diagnosis, microvascular complications, high triglyceride levels, and tobacco use were
additional independent predictors for glycemic progression. A polygenic risk score (PRS)
including 123 known risk variants for T2D also predicted rapid progression to insulin therapy
(hazard ratio [HR]: 1.07 [95% CI 1.03–1.12] per SD; P = 0.001), with validation in the replica-
tion cohort (HR: 1.24 [95% CI 1.06–1.46] per SD; P = 0.008). A PRS using 63 BMI-related
variants predicted BMI (beta [SE] = 0.312 [0.057] per SD; P = 5.84 × 10−8) but not glycemic
progression (HR: 1.01 [95% CI 0.96–1.05] per SD; P = 0.747). Limitations of this study
include potential misdiagnosis of T2D and lack of detailed data of drug use during follow-up
in the replication cohort.
Conclusions
Our results show that approximately 5% of patients with T2D failed OGLDs annually in this
clinic-based cohort. The independent associations of modifiable and genetic risk factors
allow more precise identification of high-risk patients for early intensive control of multiple
risk factors to prevent glycemic progression.
Author summary
Why was this study done?
• There is marked heterogeneity in the rate of progression to insulin requirement in
patients with type 2 diabetes (T2D). Whereas some patients can maintain optimal glyce-
mic control with oral glucose-lowering drugs for prolonged periods, others experience
rapid deterioration in glycemia, requiring early insulin treatment.
• It is important to gain insight into what factors are associated with glycemic progres-
sion. Previous studies identified baseline HbA1c, young age, and weight gain as inde-
pendent clinical predictors for glycemic progression in White populations, but there is a
paucity of data in Asians.
• Besides environmental and lifestyle factors including obesity, it is well known that
genetic factors play a pivotal role in the onset of diabetes. However, it remains unclear
whether genetic variants of body mass index (BMI) and T2D predicts glycemic
PLOS MEDICINE Predictors for glycemic progression in T2D
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progression once T2D develops. Moreover, genetic variants associated with response to
oral glucose-lowering drugs might also predict glycemic progression.
What did the researchers do and find?
• We investigated glycemic progression among 7,091 Chinese patients with T2D from the
Hong Kong Diabetes Register enrolled between 1995 and 2007. We explored the associ-
ations of clinical variables and different polygenic risk scores (PRSs) of obesity, T2D,
and response to oral glucose-lowering drugs with glycemic progression and validated
the associations of PRSs in another multicenter prospective cohort of Hong Kong Dia-
betes Biobank (HKDB).
• We found that there was an approximately 1.3-year delay of insulin use after oral glu-
cose-lowering drug failure in real-world practice.
• We observed a U-shape association between BMI and glycemic progression and found
that young age of diagnosis, high HbA1c and triglyceride, use of tobacco, and presence
of microvascular complications also predicted rapid glycemic progression.
• We found that the PRS derived from 123 known risk variants for T2D was associated
with early age of diagnosis and rapid glycemic progression, with validation in the repli-
cation cohort of HKDB, whereas the PRS derived from 63 BMI-related variants was
associated with BMI but not glycemic progression.
What do these findings mean?
• This study highlighted the delay in insulin treatment after oral glucose-lowering drug
failure, which represents an important treatment gap in clinical practice.
• This work emphasized the importance of both genetic and modifiable risk factors, nota-
bly lipo-glucotoxicity, obesity, and tobacco use on glycemic progression, which enables
identification of high-risk patients for optimal control of risk factors to improve glyce-
mic durability.
• This study provides novel insights toward the underlying pathophysiology underlining
glycemic progression, highlighting some overlap with pathogenesis of T2D.
• Our work highlights the potential utility of incorporating PRSs for drug response to
guide clinical management of T2D.
Introduction
Type 2 diabetes (T2D) is a progressive and multisystemic disease with hyperglycemia as a
major risk factor for complications [1]. Delayed intervention, patient nonadherence, heteroge-
neity of phenotypes and treatment responses can lead to different trajectories in treatment
escalation. Whereas some patients can be controlled with oral glucose-lowering drugs
(OGLDs) for decades, others experience rapid deterioration in glycemia, requiring early insu-
lin treatment [2]. In Whites with T2D, baseline HbA1c, young age, and weight gain
PLOS MEDICINE Predictors for glycemic progression in T2D
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independently predicted glycemic progression [3]. In the IMI-DIRECT study, researchers
used time to insulin initiation as an index of glycemic progression and reported that patients
with low body mass index (BMI) <24 kg/m2 and BMI >30 kg/m2 were susceptible to rapid
glycemic progression [2].
Genetic factors play a pivotal role in the onset of diabetes although this is strongly influ-
enced by environmental and lifestyle factors, notably obesity. The heritability of T2D ranges
from 30% to 70% in different populations with the discovery of a large number of genetic vari-
ants mainly implicated in beta-cell biology [4]. Although genetic analysis also supports the
causal role of obesity in T2D [5], it is unclear whether genetic variants of BMI and T2D predict
glycemic progression once T2D develops. In the IMI-DIRECT study, a high polygenic risk
score (PRS) comprising 61 risk variants of T2D was associated with a young age at diagnosis
but not time to insulin requirement in European patients [2]. Furthermore, pharmacogenetic
studies have identified variants associated with poor response to OGLD, such as metformin
[6–13], sulphonylurea (SU) [14–18], and thiazolidinediones (TZD) [19–21].
We hypothesize that clinical and genetic variants associated with T2D and response to
OGLDs predict glycemic progression in Asian patients with T2D. These predictors may iden-
tify high-risk patients for early intensification and individualization of treatment to prevent
glycemic progression and development of complications. In a prospective cohort with docu-
mentation of clinical and genetic profiles and treatment progression, we explored the associa-
tions of clinical variables and different PRSs of obesity, T2D, and response to OGLDs with
glycemic progression in insulin-naïve Chinese patients with T2D.
Materials and methods
Study population
This study utilized data from the Hong Kong Diabetes Register (HKDR) established in 1995 at
the Prince of Wales Hospital (PWH), the teaching hospital of the Chinese University of Hong
Kong [22,23]. The HKDR consecutively enrolled patients referred to the Diabetes Mellitus and
Endocrine Centre for comprehensive assessment of complications and metabolic control.
Referral sources included hospital-based specialty clinics, community clinics, and general prac-
titioners. Once registered, patients were observed to the time of death. Ethical approval was
obtained from the Clinical Research Ethics Committees of the Chinese University of Hong
Kong. Written informed consent was obtained from all participants at the time of enrollment
for collection of clinical information and biosamples for archival and research purposes. The
recruitment methods, definitions, and biochemical investigations have been described [22,24].
Between 1995 and December 31, 2007, a consecutive cohort consisting of 10,129 patients
with diabetes was assessed. After sequentially excluding 61 patients with non-Chinese or
unknown ethnicity, 400 with type 1 diabetes (T1D) or missing data on type of diabetes, 2,544
with insulin use or considered having OGLD failure at baseline (see definition below), and 33
requiring insulin within 1 year, we prospectively curated a primary cohort of 7,091 Chinese
patients with detailed information on risk factors, complications, drug use, and clinical out-
comes for further analysis (S1 Fig).
For validation of genetic association, we used an independent prospective cohort from
Hong Kong Diabetes Biobank (HKDB), which recruited patients from 11 diabetes centers at
major public hospitals across Hong Kong since 2014. Recruitment and assessment methods
were similar to that in HKDR. A total of 6,914 unrelated patients from HKDB were genotyped.
In this replication cohort, after excluding 162 patients with non-Chinese or non-T2D, 2,675
with insulin use at baseline, 3 requiring insulin within 1 year, and 135 patients who overlapped
with HKDR, we included 3,939 patients with T2D for this replication study (S2 Fig). All
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patients gave written informed consent for DNA collection and data analysis for research pur-
poses. Genetic data from HKDB became available for replication analysis around April 2019.
Baseline clinical and laboratory measurements
Clinical assessment was performed based on a modified European DiabCare protocol [25].
Details of assessment methods and definitions of clinical outcomes have been described
[24,26]. In brief, all patients in the HKDR and HKDB underwent clinical assessments and lab-
oratory investigations after 8-hour overnight fast, including eye, feet, urine, and blood exami-
nations. Eye examination included visual acuity and fundoscopy through dilated pupils or
retinal photography. Retinopathy was defined by typical changes due to diabetes, laser scars,
or a history of vitrectomy. Foot examination was performed using Doppler ultrasound scan
and monofilament and graduated tuning fork. Fasting blood was sampled for measurement of
plasma glucose, HbA1c, and lipid profile (total cholesterol, high-density lipoprotein choles-
terol [HDL-C], triglycerides, and calculated low-density lipoprotein cholesterol [LDL-C]), and
random spot urinary sample was used to assess albumin-to-creatinine ratio (ACR). The
Chronic Kidney Disease Epidemiology Collaboration equation was used to estimate glomeru-
lar filtration rate (eGFR) [27].
Definition of clinical outcomes
Clinical outcomes were defined using hospital discharge diagnoses based on the International
Classification of Diseases, Ninth Revision (ICD-9) and mortality as censored on or before June
30, 2014. The Hong Kong Hospital Authority Central Computer System records admissions to
all public hospitals, which provides about 95% of inpatient bed-days in Hong Kong. All hospi-
talization records were retrieved from this system using a unique identifier number. Given the
frequent delay in starting insulin due to patients’ reluctance or clinicians’ delayed decision, we
used a composite end point for “requirement of insulin treatment” to define glycemic progres-
sion, (1) progression to continuous insulin treatment (more than 6 months’ duration), or (2)
failure of OGLDs (2 consecutive HbA1c�8.5%, more than 3 months apart during treatment
with�2 OGLDs [metformin, SU, or TZD]), in line with the definition used in the IMI-DIR-
ECT study [2]. Follow-up time was defined as the period from baseline visit to the date of the
first clinical end point or the censored dates, whichever came first. Since the OGLD data dur-
ing follow-up in the HKDB were not available for this analysis, we used continuing insulin
treatment as the end point in the replication cohort.
PRS
In a subset of 4,423 patients from the primary cohort with genome-wide association study
(GWAS) data, we developed 6 different PRSs using published genetic variants associated with
T2D, BMI, or response to OGLDs. We investigated the associations between glycemic progres-
sion and each PRS, including (1) European-T2D PRS derived from 143 single nucleotide poly-
morphisms (SNPs) identified in a meta-analysis of GWAS in European populations [4], (2)
Asian-T2D PRS derived from 48 SNPs including those identified in Asian-GWAS or European
SNPs replicated in East Asians [28], (3) BMI PRS derived from 97 SNPs associated with BMI
[29,30], (4) metformin PRS derived from 8 SNPs associated with metformin response [6–13],
(5) SU PRS derived from 7 SNPs associated with SU response [14–18], and (6) TZD PRS
derived from 3 SNPs associated with TZD response [19–21]. All SNPs in PRS associated with
BMI and drug responses were discovered in European populations.
We extracted these SNPs from imputed genotyping data using the Illumina Omni 2.5
+ exome array (Illumina, San Diego, CA). We selected independent common SNPs (linkage
PLOS MEDICINE Predictors for glycemic progression in T2D
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003209 July 28, 2020 5 / 19
disequilibrium [LD] coefficient r2 < 0.5; minor allele frequency [MAF] > 0.01) available in
our dataset with good genotyping quality to construct the final PRSs. Standard quality con-
trol (MAF > 0.01; call rate > 97%; P> 0.0001 in Hardy-Weinberg equilibrium) was per-
formed and genotype data were imputed using minimac3 with the 1000 Genomes Project
phase 3 v5 as reference panel [23]. Finally, we obtained 123, 48, 63, 8, 7, and 3 independent
common SNPs to develop the European-T2D, Asian-T2D, BMI, metformin, SU, and TZD
PRSs, respectively (S1–S6 Tables). Because of the small number of SNPs associated with each
OGLD, we created a combined PRS using all 18 SNPs for drug responses. Each PRS was first
constructed by summing the score of reported risk allele for each SNP based on an additive
genetic model and then rescaled to a score to express the standard deviation (SD) using the
following formula: (individual PRS value − population mean PRS)� population SD of PRS.
The final analysis is based on (1) the genetic risk per SD of the standardized PRS and (2) ter-
tile analysis of the PRS for glycemic progression (tertile 1: low; tertile 2: intermediate, and
tertile 3: high).
In the replication cohort, we performed genotyping using the Illumina Infinium Global
Screening Array (GSA) and conducted quality control and imputation using similar criteria. A
proxy SNP with r2 >0.6 (according to the 1000 Genome CHB panel) was selected when the
index SNP was imputed with poor quality. One European-T2D variant (rs17405722 near
STAT3 gene) with poor proxies was dropped, and 1 SU variant (rs1801278 in IRS1 gene) was
replaced with a proxy variant (rs56171406; r2 = 1).
Statistical analysis
We used Cox proportional hazards regression model for prospective analysis. We examined
the Cox proportional hazards assumption by plotting the scaled Schoenfeld residuals against
log-transformed time for each covariate and further tested the assumption via the test pro-
posed by Grambsch and Therneau [31]. As suggested by reviewers, we used 3-knot restricted
cubic spline to plot the relationship between BMI as a continuous variable (rather than BMI
categories) and glycemic progression. Because of the nonlinear relationship between BMI and
rate of progression to insulin requirement, we divided BMI into 4 groups using the World
Health Organization (WHO) Asian definition for obesity—underweight (BMI < 18.5 kg/m2),
normal (�18.5–23.0 kg/m2), overweight (�23.0–25.0 kg/m2), and obese (�25.0 kg/m2)—for
the survival analysis [32]. We assessed crude survival (for non-insulin requirement) with the
Kaplan-Meier estimator, stratified for BMI categories. Since the proportional hazard assump-
tion for baseline HbA1c was not met, we stratified the cohort into 3 groups (HbA1c< 7%,�
7–9%, and� 9%) to allow for a different hazard function in each group. Both BMI and HbA1c
categories were included as strata variables in Cox models, whereas other covariates were con-
sidered to have same effect across strata. A procedure of stepwise model selection by the
Akaike information criterion (AIC) was employed to identify clinical predictors for glycemic
progression in multivariate analysis. Linear regression was used to examine associations
between PRSs and quantitative traits.
All data were expressed as percentages; means and SDs; or medians and interquartile ranges
(IQRs) as appropriate. All statistical tests were 2-sided, and a P value <0.05 was considered to
be significant. Analyses were performed using R (version 3.1.0; http://www.R-project.org).
Results
Baseline characteristics of the study population
Among 7,091 patients included in the analysis (mean age 56.8 ± 13.3[SD] years; 47% men;
median duration of diabetes 4 [IQR: 1–9] years), 3,111 (43.9%) had glycemic progression
PLOS MEDICINE Predictors for glycemic progression in T2D
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during a median follow-up period of 8.8 (IQR: 4.8–13.3) years. The incident rate of glycemic
progression was 48.0 (95% confidence interval [CI] 46.3–49.8) per 1,000 person-years. The
median period from diagnosis of T2D to glycemic progression was 13.7 (IQR: 9.3–18.7) years.
Among the progressors, 2,519 were actually started on insulin, with 33.2% of them (n = 836)
experiencing a median lag period of 1.3 (IQR: 0.4–3.0) years before insulin was initiated. Com-
pared with nonprogressors, patients with glycemic progression had younger age of diagnosis;
longer duration of diabetes; and higher BMI, HbA1c, triglyceride, LDL-C, and urinary ACR
and were more likely to be smokers and have microvascular complications (Table 1). In the
replication cohort comprising 3,939 patients, 172 (4.4%) had glycemic progression during a
Table 1. Baseline characteristics of progressors and nonprogressors for glycemic deterioraton, defined as need for insulin treatment in the primary cohort.
Characteristics Nonprogressors Progressors P
N 3,980 3,111
Age (year) 58.28 ± 13.09 54.84 ± 13.23 <0.001
Age at diagnosis (year) 53.4 ± 12.52 48.18 ± 12.35 <0.001
Young age at diagnosis (<40 years) 14.35% (558) 25.28% (778) <0.001
Year of diagnosis 1996 (1992–2002) 1994 (1989–1998) <0.001
Male sex 45.95% (1,829) 47.19% (1,468) 0.302
Duration of diabetes (year) 3 (1–8) 5 (2–10) <0.001
Smoking status <0.001
Former 15.38% (609) 16.18% (502)
Current 10.98% (435) 14.89% (462)
BMI (kg/m2) 25.18 ± 3.92 25.39 ± 4.11 0.031
HbA1c (%) 6.87 ± 1.39 8.02 ± 1.86 <0.001
Triglyceride (mmol/L) 1.34 (0.95–1.96) 1.47 (1.01–2.2) <0.001
HDL-C (mmol/L) 1.34 ± 0.36 1.28 ± 0.35 <0.001
LDL-C (mmol/L) 3.05 ± 0.95 3.21 ± 1 <0.001
Systolic BP (mmHg) 134.17 ± 20.24 134.72 ± 20.63 0.265
Diastolic BP (mmHg) 75.6 ± 11.07 76.71 ± 10.81 <0.001
Urinary ACR (mg/mmol) 1.37 (0.64–4.98) 2.26 (0.86–10.9) <0.001
eGFR (mL min−1 per 1.73 m2) 104.84 (86.51–123.78) 108.04 (87–130.26) <0.001
Sensory neuropathy 16.38% (652) 22.18% (690) <0.001
Retinopathy 17.11% (681) 25.2% (784) <0.001
Stroke history 3.02% (120) 1.51% (47) <0.001
CKD history 10.1% (402) 11.12% (346) 0.165
PVD history 4.75% (189) 4.98% (155) 0.65
CHD history 7.09% (282) 6.27% (195) 0.173
Baseline drug treatment
Lipid-lowering drugs 17.19% (684) 13.69% (426) <0.001
BP-lowering drugs 44.1% (1,755) 38.67% (1,203) <0.001
ACEIs or ARBs 17.56% (699) 17.9% (557) 0.709
Oral glucose-lowering drugs 62.74% (2,497) 70.43% (2,191) <0.001
Data are expressed as mean ± standard deviation, percentage (number), or median (interquartile range); t test or Mann-Whitney rank sum test was used for the
continuous variables, and χ2 test was used for the categorical variables.
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ACR, albumin-to-creatinine ratio; ARB, angiotensin receptor block; BMI, body mass index; BP, blood
pressure; CHD, coronary heart disease; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C,
low-density lipoprotein cholesterol; PVD, peripheral vascular disease
https://doi.org/10.1371/journal.pmed.1003209.t001
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median follow-up period of 1.9 (IQR: 1.5–2.3) years. Progressors had younger age of diagnosis,
longer duration of diabetes, and higher HbA1c and triglyceride (S7 Table).
Association of clinical factors with diabetes progression
There was a U-shape association between BMI and glycemic progression (P< 0.001 for non-
linearity; Fig 1) after adjustment for age at diagnosis, gender, duration of diabetes, year of diag-
nosis, smoking status, LDL-C, HbA1c, triglyceride, urinary ACR, eGFR, retinopathy, sensory
neuropathy, history of chronic kidney disease (CKD), and use of different medications (yes/
no). Compared with those with a normal BMI of 18.5–23 kg/m2, patients with low BMI<18.5
kg/m2 had a hazard ratio (HR) of 1.66 (95% CI 1.31–2.10), and those with obesity (BMI� 25.0
kg/m2) had an HR of 1.12 (95% CI 1.02–1.22) after adjustment for conventional risk factors.
On Kaplan-Meier analysis, patients with low BMI (<18.5 kg/m2) had the fastest rate of glyce-
mic progression (Fig 2). Compared with patients with HbA1c <7%, those with HbA1c of 7%–
9% had an HR of 2.14 (95% CI 1.93–2.36), and those with HbA1c >9% had an HR of 4.07
(95% CI 3.63–4.56) for glycemic progression. Patients diagnosed before the age of 40 had an
HR of 1.28 (95% CI 1.18–1.39), compared with those diagnosed after age of 40 years. Within
the BMI and HbA1c strata, the multivariate Cox model derived from stepwise selection shows
that young age at diagnosis; long disease duration; active/ex-smoking status; high urinary ACR
and triglyceride; presence of retinopathy, neuropathy, and CKD; and use of OGLDs were inde-
pendent predictors for glycemic progression (Table 2).
Fig 1. HRs of BMI as a continuous variable and glycemic progression. The dashed line is the reference line at
HR = 1. The solid curve and the shaded areas stand for the HRs and their 95% CIs for glycemic progression,
respectively. HRs were adjusted for age at diagnosis, gender, duration of diabetes, year of diagnosis, smoking status,
LDL-C, HbA1c, log triglyceride, log urinary ACR, eGFR, retinopathy, sensory neuropathy, history of chronic kidney
disease, and use of different medications (yes/no). ACR, albumin-to-creatinine ratio; BMI, body mass index; CI,
confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; LDL-C, low-density lipoprotein
cholesterol.
https://doi.org/10.1371/journal.pmed.1003209.g001
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Association of PRS with glycemic progression
After adjusting for clinical predictors (Fig 3 and S8 Table), the PRS of 123 European-T2D
SNPs was independently associated with glycemic progression (HR: 1.07 [95% CI 1.03–1.12]
per SD; P = 0.001). Among the 3 PRSs related to drug response, the metformin PRS was associ-
ated with glycemic progression (HR: 1.07 [95% CI 1.02–1.12] per SD; P = 0.005). The top ter-
tile of the composite PRS for drug response showed nominal significance with glycemic
progression, compared with the reference group with a HR of 1.22 (95% CI 1.03–1.45;
P = 0.022) (S8 Table). No significant associations were found for other PRSs or individual risk
variant (S1–S6 Tables).
On multivariate linear regression with adjustment for confounding factors, the European-
T2D PRS and Asian-T2D PRS were associated with earlier age at diagnosis (beta [SE] = −0.617
[0.155] per SD; P = 6.58 × 10−5 and beta [SE] = −0.817 [0.154] per SD; P = 1.24 × 10−7, respec-
tively), whereas the BMI PRS was associated with baseline BMI (beta [SE] = 0.312 [0.057] per
SD; P = 5.84 × 10−8; S8 Table).
In the replication HKDB cohort including 3,939 patients (mean age 60.9 ± 10.9 years;
59.5% men; median duration of diabetes 7 [IQR: 3–13] years), 172 (4.4%) progressed to insulin
use during a median follow-up period of 1.9 (IQR: 1.5–2.3) years. The risk association of Euro-
pean-T2D PRS with glycemic progression was significant after adjusting for confounding fac-
tors (HR: 1.24 [95% CI 1.06–1.46] per SD; P = 0.008) (S9 Table) but not for the metformin
PRS. The European-T2D PRS and Asian-T2D PRS were associated with age at diagnosis,
whereas the BMI PRS was associated with baseline BMI (S9 Table).
Sensitivity analysis
We performed the following sensitivity analyses to assess the robustness of our findings. First,
we repeated the analysis by defining the subcomponent of glycemic progression using the end
Fig 2. Survival curves for 4 BMI categories according to the World Health Organization definition for obesity in
Asians. BMI, body mass index.
https://doi.org/10.1371/journal.pmed.1003209.g002
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Table 2. Multivariate Cox proportional hazards model derived from stepwise model selection by the Akaike infor-
mation criterion for diabetes progression.
Covariate HR (95% CI) P
Age at diagnosis (per 1 year) 0.98 (0.97–0.98) <0.001
Year of diagnosis (per 1 year) 1.03 (1.01–1.05) 0.001
Duration of diabetes (per 1 year) 1.05 (1.03–1.07) <0.001
Smoking
Ex-smoker 1.38 (1.22–1.57) <0.001
Current smoker 1.15 (1.01–1.32) 0.038
log (triglyceride) 1.11 (1.01–1.22) 0.029
LDL-C 0.96 (0.91–1.01) 0.131
log urinary ACR 1.15 (1.11–1.19) <0.001
eGFR 0.998 (0.996–1.001) 0.064
Sensory neuropathy 1.27 (1.13–1.42) <0.001
Retinopathy 1.28 (1.14–1.43) <0.001
CKD history 1.67 (1.38–2.02) <0.001
Use of lipid-lowering drugs 0.89 (0.77–1.04) 0.139
Use of ACEIs or ARBs 1.12 (0.98–1.27) 0.104
Use of oral glucose-lowering drugs 1.37 (1.22–1.53) <0.001
BMI and baseline HbA1c categories were included as strata variables. BMI was categorized as 4 groups (<18.5, 18.5–
23, 23–25, and�25 kg/m2) and baseline HbA1c was categorized as 3 groups (<7%,�7%–9%, and�9%).
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor block; BMI, body mass
index; CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HR, hazard
ratio; LDL-C, low-density lipoprotein cholesterol
https://doi.org/10.1371/journal.pmed.1003209.t002
Fig 3. Association between PRSs and progression to requirement of insulin treatment. HRs were adjusted for all clinical risk
factors identified by stepwise variable selection, including age at diagnosis, gender, duration of diabetes, year of diagnosis,
smoking status, LDL-C, HbA1c, log triglyceride, log urinary ACR, eGFR, retinopathy, sensory neuropathy, history of chronic
kidney disease, and use of different medications (yes/no). Number of progressors versus nonprogressors was presented in
parentheses for each subgroup. ACR, albumin-to-creatinine ratio; eGFR, estimated glomerular filtration rate; HR, hazard ratio;
LDL-C, low-density lipoprotein cholesterol; PRS, polygenic risk score; SD, standard deviation; SNP, single nucleotide
polymorphism; SU, sulphonylurea; TZD, thiazolidinediones.
https://doi.org/10.1371/journal.pmed.1003209.g003
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point of continuing insulin treatment. After excluding 461 non-Chinese or non-T2D patients,
2,061 insulin-treated patients at baseline, and 37 patients initiated on insulin within 1 year of
enrollment, we obtained a prospective cohort of 7,570 patients for this sensitivity analysis.
During a median of 9.3 (IQR: 5.4–13.6) follow-up years, 38.1% (N = 2,882) required continu-
ing use of insulin. Within this cohort, 4,475 patients had genotyping data. The associations
between PRSs and insulin initiation were largely unchanged. The European-T2D PRS and
metformin PRS were associated with progression to insulin use (HR: 1.07 [95% CI 1.02–1.12]
per SD, P = 0.004; 1.06 [95% CI 1.01–1.11] per SD, P = 0.013, respectively) (S10 Table). No sig-
nificant associations were found for the other PRSs (S10 Table).
Second, since HDL-C was independently associated with progression to insulin in Euro-
pean patients [2], we replaced triglyceride and LDL-C with HDL-C in multivariate Cox analy-
sis and confirmed its association with glycemic progression in our cohort (HR: 0.85 [95% CI
0.74–0.98], P = 0.025; S11 Table). We weighted the European-T2D and Asian-T2D PRS using
the logarithm of the allelic odds ratio of the SNP as reported in the meta-analyses and exam-
ined the associations with glycemic progression. The results were similar to that from the
unweighted PRS (HR: 1.06 [95% CI 1.01–1.11] per SD; P = 0.013 for the European-T2D PRS).
Third, taking into consideration of the relationship between BMI and T2D, some T2D-
related SNPs may be associated with BMI. Therefore, following suggestions from reviewers,
we updated the European-T2D PRS and Asian-T2D PRS by excluding those BMI-related
SNPs and examined the associations between the updated PRSs and glycemic progression. We
first checked for LD between the European T2D–related SNPs, or Asian T2D–related SNPs,
and the list of SNPs associated with BMI using data from 1000 Genome project and data for
Han Chinese population (CHB). We found that in the European T2D–related SNPs, a total of
7 SNPs (rs2867125, rs2972144, rs2307111, rs72892910, rs7903146, rs7185735, and rs12970134)
had r2 >0.6 with any one of the BMI-related SNPs on the same chromosome. For the Asian
T2D–related SNPs, we identified 4 SNPs (rs2943641, rs7903146, rs9939609, and rs12970134)
that had r2 >0.6 with any one of the BMI SNPs on the same chromosome. After exclusion of
these SNPs with high LD with BMI-related SNPs, we reconstructed the European-T2D PRS
and Asian-T2D PRS and repeated the analysis. The results showed that the association between
the European-T2D PRS was similar to the results of our original analysis (S12 Table). Further-
more, we identified 17 SNPs from the European T2D–related SNPs, which showed significant
association at level of 0.05 with baseline BMI in our primary cohort of HKDR. The identities
of these SNPs are rs780094, rs12617659, rs13389219, rs4865796, rs459193, rs10077431,
rs7756992, rs853974, rs12681990, rs516946, rs10811661, rs2796441, rs2237892, rs576674,
rs963740, rs982077, and rs8108269. Likewise, 11 SNPs from the list of Asian T2D–related
SNPs showed association with baseline BMI (rs780094, rs3923113, rs1470579, rs459193,
rs7756992, rs791595, rs7041847, rs10811661, rs2796441, rs2237892, and rs7178572). We fur-
ther removed these SNPs from the respective European-T2D PRS and Asian-T2D PRS, in
addition to removing the SNPs with high LD with BMI-related SNPs, and repeated the associa-
tion analysis. Interestingly, the association between the European-T2D PRS and diabetes pro-
gression became stronger, whereas the results for the Asian-T2D PRS and diabetes
progression remained similar, with no evidence of association (S12 Table). Replication analy-
ses in the HKDB showed similar results (S13 Table).
Fourth, in order to explore the impact of the different drug response PRS stratified accord-
ing to prescribed drugs, we investigated the associations of metformin PRS and SU PRS with
glycemic progression by stratifying the exposure time of each oral drug among new users of
oral drug by dividing into tertiles according to duration of drug exposure during follow-up.
The interaction term between duration of metformin exposure and metformin PRS was not
significantly associated with glycemic progression. However, the HR for metformin PRS
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increased with increasing exposure to metformin during the follow-up period, with nominal
significance for the high-exposure subgroup (HR: 1.16 [95% CI 1.01–1.33]; P = 0.04), with
adjustment for confounding factors (S14 Table). However, no significant association was
observed for the metformin PRS if stratified according to duration of exposure to SU.
Although the sample size was significantly reduced because of exclusion of prevalent drug
users in each group and the smaller subgroups, this provides suggestive evidence that the asso-
ciation between metformin PRS and glycemic progression in users of metformin is mainly
driven by those with longer duration of exposure to the drug.
Fifth, as the replication cohort, HKDB, included patients with a longer duration of diabetes
and worse renal function compared with those in HKDR, we investigated the potential impact
of CKD on the associations of PRS and glycemic progression. After excluding 688 with history
of CKD, 3,251 patients from HKDB were included in this analysis (mean age 59.5 ± 10.6 [SD]
years; 58.8% men; median duration of diabetes 6 [IQR: 2–12] years; median eGFR 90.2 [IQR:
78.5–98.7]). Among them, 127 (3.9%) had glycemic progression during a median follow-up
period of 1.9 (IQR: 1.6–2.3) years, which was similar with the original analysis of HKDB. Anal-
ysis of different PRSs and glycemic progression in this subcohort gave similar results to that
obtained from the main analysis, with only the European-T2D PRS replicated to be associated
with glycemic progression (HR: 1.25 [95% CI 1.03–1.51] per SD; P = 0.023).
Finally, we explored potential misclassification of T2D in a subgroup of patients with avail-
able glutamic acid decarboxylase antibodies (GADA) data measured for research purpose and
not for clinical indication. In this subgroup of 983 patients (91% [N = 895] with young-onset
diabetes), 6.8% (N = 67) were GADA positive (�5 μg/mL). The proportions of patients with
positive GADA in different BMI categories of<18.5, 18.5–23, 23–25, and�25 kg/m2 were
19.4% (n = 6), 9.3% (N = 24), 4.9% (N = 9), and 5.5% (N = 28), respectively. Exclusion of
patients with GADA did not influence the results.
Discussion
There is considerable heterogeneity in glycemic progression in T2D. In this prospective cohort of
the HKDR, we analyzed time to requirement or initiation of insulin in patients with T2D followed
for a median duration of 8.8 years. Our main findings were 3-fold. First, there was an approxi-
mately 1.3-year delay of insulin use after OGLD failure in real-world practice. Second, young age
of diagnosis, high HbA1c and triglyceride, extremes of BMI, use of tobacco, and microvascular
complications predicted rapid glycemic progression [2,3]. Third, genetic variants associated with
T2D in European populations predicted early age of diagnosis and rapid glycemic progression.
These findings emphasize the importance of both genetic and modifiable risk factors, notably
lipo-glucotoxicity, obesity, and tobacco use on glycemic progression, which enables identification
of high-risk patients for optimal control of risk factors to improve glycemic durability.
Among progressors to insulin requirement, 33.2% experienced delay of 1.3 years before
actual initiation of insulin. Compared with nonprogressors or those with more prompt insulin
initiation, patients with delayed insulin treatment were younger and had shorter disease dura-
tion, lower blood pressure, and higher BMI. In a recent study from the United States, approxi-
mately 30% of patients with T2D had delayed insulin therapy, with an average lag period of 2
years [33]. In our analysis, the presence of microvascular complications was associated with
earlier start of insulin, raising the possibility that delayed insulin and increased glycemic bur-
den might contribute to increased risk of complications especially in young patients [34].
Inconvenience, fear of injection, insufficient empowerment, physicians’ concerns of patient
nonadherence, and lack of supporting system might delay insulin initiation [35,36]. These bar-
riers can be overcome by the use of team-based care with focus on education/self-care, task
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shifting (e.g., using nurse educator), and providing feedback to promote physician-patient
communication, especially in low-resource settings [37].
It is well established that smoking is an independent risk factor for T2D [38], but our study
further revealed that smoking can also influence the glycemic progression once T2D is diag-
nosed, suggesting that cessation of smoking is a key factor for prevention and management of
T2D. Similar to reports in European populations [2], extremes of BMI predicted glycemic pro-
gression in our population, but not BMI PRS. The association of high BMI might be more
related to lifestyle factors, whereas low BMI might be associated with atypical forms of diabetes
due to autoimmunity or uncommon genetic variants. Indeed, in a subgroup analysis, 1 in 5
patients with BMI <18 kg/m2 had GADA. Although our sample size had 87% power to detect
an association between BMI PRS and glycemic progression at α-level of 0.05, assuming an HR
of 1.07, only 0.5% variance of BMI was explained by the PRS, comprising 63 risk variants.
There are relatively few GWASs on obesity in Asians, and more BMI-related genetic variants
are needed to validate the genetic association of obesity and glycemic progression.
In the IMI-DIRECT study including 5,250 patients with T2D, a high PRS derived from 61
T2D risk variants predicted young age at diagnosis but not glycemic progression [2]. In this
larger cohort including over 7,000 Chinese patients with T2D, we derived a European-T2D
PRS using 123 variants that predicted age at diagnosis and glycemic progression. The Asian-
T2D PRS also predicted age at diagnosis but not glycemic progression. The considerably fewer
Asian-T2D SNPs compared with the European-T2D SNPs might have reduced the power of
the study. However, using progression to insulin as an end point in a subgroup analysis, the
association with Asian-T2D PRS was validated. Given the small effect size of these common
SNPs, the use of genome-wide PRS based on thousands of SNPs may further improve the dis-
criminative performance in predicting complex traits [39]. For genetic risk of drug responses,
only the metformin PRS predicted rapid glycemic progression, albeit not replicated in the
HKDB cohort. We did not find any associations with SU PRS and TZD PRS. These negative
associations may be due to secular changes in drug use between the primary and replication
cohorts. Over 90% of patients were treated with metformin-based therapy in the primary cohort
established since 1997, whereas newer drugs (e.g., dipeptidyl peptidase-4 [DPP-4] inhibitors)
were more frequently prescribed in the replication cohort established since 2014. Small sample
size, long disease duration, and short period of follow-up in the replication cohort may also
reduce its power to detect the association. There are few pharmacogenetic studies in Asian pop-
ulation on OGLDs, calling for more large-scale GWASs to fill this knowledge gap.
One of the important applications from the use of such PRS in our study is to identify
potentially important pathways involved in glycemic progression and generate new etiological
insights. SNPs associated with T2D are most commonly associated with beta-cell function,
highlighting the potential central role of beta-cell dysfunction in both the pathogenesis of T2D
and glycemic progression following onset of T2D. The lack of association between the PRS for
BMI and glycemic progression suggests that weight loss alone, although useful to improve met-
abolic control, may not have sustained effects on slowing glycemic deterioration. Recent stud-
ies in mainly European cohorts have generated phenotyped-based clusters, pathophysiology-
based clusters, and PRSs that reflect different pathophysiological processes ranging from beta-
cell dysfunction to adiposity to lipodystrophy [40–42]. Although beyond the scope of the cur-
rent manuscript, we plan to explore the importance of these pathophysiological defects in rela-
tion to glycemic progression using these pathway-based PRSs in future analyses. The fact that
over 90% of patients in HKDR were treated with metformin at some stage, and the association
between metformin PRS and glycemic progression, highlights the potential utility for precision
medicine in diabetes, whereby genetic determinants of response to key glucose-lowering drugs
have important modulating effects on disease progression, and therefore can be used to guide
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treatment escalation. On the basis of findings from the current study, we have already
embarked on translational studies to evaluate the use of such biomarker information to guide
clinical treatment decisions.
We acknowledge several limitations in our study. First, despite excluding patients with T1D
and those requiring insulin within 1 year of diagnosis, it remains possible that some patients
were misdiagnosed as T2D, especially for those with low BMI. In a sensitivity analysis of a sub-
group of patients, predominantly those with young-onset diabetes who had available GADA
data, approximately 7% had positive GADA [43]. Although there were more patients with pos-
itive GADA in the low-BMI group compared with the other groups (19% versus 5%–10%),
only 25% of patients had low BMI, and thus the impact of misclassification was only modest.
However, measurement of these biomarkers, especially in young and/or lean patients, may
avoid undue delay in insulin treatment. In the United Kingdom Prospective Diabetes Survey
involving 3,672 patients with T2D, GADA (defined as titer>20 U/L by a radioimmunopreci-
pitation assay) was present in 9.8% of adult patients, who were more likely to require insulin
within 6 years of diagnosis than those without GADA [44]. Second, since different definitions
of phenotypes, especially for drug response, were used in previous studies together with some
variants not being identified in our GWAS dataset, we did not weigh the PRSs using the
reported effect sizes of these risk alleles. However, we used weighted European-T2D PRS and
found similar results in the sensitivity analysis. Third, we did not have a replication cohort
with detailed follow-up data of drug use as the primary cohort. However, the associations
between clinical variables and end point were similar in both discovery/validation cohorts and
consistent with previous studies.
In conclusion, in Chinese patients with T2D, extremes of BMI were associated with rapid
glycemic progression, suggesting heterogeneous etiologies and effects of obesity in T2D.
Young age at diagnosis, long disease duration, suboptimal lipid and glucose control, tobacco
use, microvascular complications, and genetic variants of T2D all independently predicted gly-
cemic progression or requirement of insulin treatment. Our study suggests potential overlap
between the pathogenesis of T2D and glycemic progression. The contributions of both modifi-
able and nonmodifiable risk factors enable the precise identification of high-risk individuals
for close monitoring and early treatment intensification to maintain glycemic durability.
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